Physician profile
Nickolas Leaf
NPI 1245904200
$504.94
in general payments reported to CMS, 2019-2025
15 companies · $217 in 2025
The $217 reported for 2025 was more than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $17.77 · 2022: $98.97 · 2023: $121 · 2024: $50.18 · 2025: $217.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $388.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $388.20 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Boston Scientific Corporation | $80.47 | 2025 | Intracept |
| Abbvie INC. | $69.76 | 2023 | |
| Lilly USA, LLC | $59.77 | 2022-2024 | Mounjaro, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $44.14 | 2025 | Relistor |
| Genentech USA, INC. | $38.72 | 2021-2022 | |
| Averitas Pharma INC. | $37.54 | 2025 | Qutenza |
| Smith+Nephew, INC. | $34.88 | 2025 | Collagenase Santyl |
| Pfizer INC. | $25.90 | 2022 | |
| Vertex Pharmaceuticals Incorporated | $19.93 | 2025 | |
| Janssen Pharmaceuticals, INC | $19.86 | 2023 | Xarelto |
| Novo Nordisk INC | $17.67 | 2023 | Ozempic, Rybelsus |
| Boehringer Ingelheim Pharmaceuticals, INC. | $14.74 | 2022 | |
| Phathom Pharmaceuticals, INC. | $13.98 | 2024 | Voquezna |
| Astrazeneca Pharmaceuticals Lp | $13.81 | 2024 | Airsupra |
| Exact Sciences Corporation | $13.77 | 2023 | Cologuard Collection Kit |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Nickolas Leaf listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.